Status:
UNKNOWN
The Hepatitis C Transplant Collaborative
Lead Sponsor:
Baylor Research Institute
Conditions:
Transplant; Failure, Heart
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.
Detailed Description
Organ offers from donors with prior or chronic hepatitis C virus (HCV) exposure have been historically underutilized for orthotopic heart transplantation because of the post-transplantation risks \[1,...
Eligibility Criteria
Inclusion
- Recipient of a proven HCV NAT+ donor heart.
- Re-transplant patients will be included.
Exclusion
- 1\. Multi-organ transplantation
Key Trial Info
Start Date :
September 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04493385
Start Date
September 16 2019
End Date
December 1 2023
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor Scott & White Health Research Institute
Dallas, Texas, United States, 75246